Human gene
IL2RG interleukin 2 receptor, gamma
2 disease groups in OMIA reach this gene, through the animal gene that Ensembl gives as its ortholog. The page shows the chain. It does not say whether an animal is a model of a human disease.
Animal diseases
By each group's best natural-model score, highest first. How the score works.
| OMIA group | Name | Species | Animal gene | Ortholog | The chain reached | Best score |
|---|---|---|---|---|---|---|
| 899 | Severe combined immunodeficiency disease, X-linked | dog | IL2RG | one to one | Drug |
72.4
|
| 899 | Severe combined immunodeficiency disease, X-linked | golden hamster | Il2rg | one to one | Drug |
72.4
|
| 899 | Severe combined immunodeficiency disease, X-linked | pig | IL2RG | one to one | Drug |
72.4
|
| 2763 | Severe combined immunodeficiency disease, IL2RG and RAG1-related | crab-eating macaque | IL2RG | one to one | Drug |
47.2
|
Target evidence
Each Open Targets association between this gene and a human disease that a disease group reached.
| Human disease | Mondo | Score | Evidence |
|---|---|---|---|
| T-B+ severe combined immunodeficiency due to gamma chain deficiency | MONDO:0010315 | 0.85 | 628 |
| combined immunodeficiency, X-linked | MONDO:0010730 | 0.74 | 31 |
| severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive | MONDO:0011086 | 0.05 | 1 |
Drugs
Each ChEMBL drug that acts on this gene.
| Drug | How | Latest stage |
|---|---|---|
| Aldesleukin | agonist | Approved |
| Basiliximab | inhibitor | Approved |
| Daclizumab | inhibitor | Approved |
| Denileukin Diftitox | binding agent | Approved |
| Nogapendekin Alfa Inbakicept | agonist | Approved |
| Simlukafusp Alfa | binding agent | Phase 3 |
| Pegenzileukin | agonist | Phase 2 |
| Recombinant Human Interleukin-15 | agonist | Phase 2 |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.